

COMPANY OVERVIEW

Cocrystal Pharma, Inc. is a clinical stage biotechnology company seeking to discover and develop novel antiviral therapeutics as treatments for serious and/or chronic viral diseases. We employ unique structure-based technologies and Nobel Prize winning expertise to create first- and best-in-class antiviral drugs. These technologies are designed to efficiently deliver small molecule therapeutics that are safe, effective and convenient to administer. We have identified promising preclinical and early clinical stage antiviral compounds for unmet medical needs including Influenza Virus, Coronavirus, Hepatitis C virus ("HCV"), and Norovirus infections.

RECENT NEWS

Cocrystal Pharma to Present at the H.C. Wainwright 22nd Annual Global Investment Conference

Sep 8 2020, 8:00 AM EDT

Cocrystal Pharma Announces Closing of \$17.2 Million Bought Deal Including Partial Exercise of Underwriter's Option to Purchase Additional Shares

Aug 31 2020, 12:05 PM EDT

Cocrystal Pharma Increases Previously Announced Bought Deal to \$15.0 Million

Aug 26 2020, 10:00 PM EDT

STOCK OVERVIEW

Symbol	COCP
Exchange	Nasdaq
Market Cap	65.34m
Last Price	\$0.953
52-Week Range	\$0.3861 - \$3.04

09/28/2020 04:00 PM EDT

INVESTOR RELATIONS

JTC Team, LLC
Jenene Thomas
T: 833-475-8247
cocp@jtcir.com

MANAGEMENT TEAM

Gary Wilcox, Ph.D.

Chairman of the Board and Chief Executive Officer

Sam Lee, Ph.D.

President

James J. Martin

Chief Financial Officer

COCRYSTAL PHARMA, INC.

19805 North Creek Parkway
Bothell, WA 98011
US

DISCLAIMER

Except for the historical information contained here in, the matters discussed in this document are forward-looking statements that involve risks and uncertainties, including but not limited to business conditions and the amount of growth in our industry and general economy, competitive factors, and other risks detailed from time to time in the Company's SEC reports, including but not limited to its annual reports on form 10-K and its quarterly reports on Form 10-Q. The company does not undertake any obligation to update forward-looking statements. All trademarks and brand name are the property of their respective companies.